Source comparison
Comparison: Sermorelin Response Timeline vs Other Secretagogues
How does sermorelin's timeline compare to other peptides researchers use to elevate growth hormone signaling? Sermorelin Acetate GHRH receptor agonist (pituitary) 2–4 weeks 8–12 weeks Real Peptides synthesis with verified amino-acid sequencing GHRP-2 Ghrelin r
This comparison does not assign a generated winner or score.
- How does sermorelin's timeline compare to other peptides researchers use to elevate growth hormone signaling?
- Sermorelin Acetate
- GHRH receptor agonist (pituitary)
- 2–4 weeks
- 8–12 weeks
- Real Peptides synthesis with verified amino-acid sequencing
- GHRP-2
- Ghrelin receptor agonist (pituitary + hypothalamus)
- 1–2 weeks
- 6–8 weeks
- Available via GHRP-2 for controlled research
- Ipamorelin
- Selective ghrelin receptor agonist
- 2–3 weeks
- 8–10 weeks
- Requires HPLC verification. Purity variance is high across suppliers
- MK-677 (Ibutamoren)
- Oral ghrelin mimetic (non-peptide)
- 4–6 weeks
- MK-677 oral formulation. Longer half-life than injectable peptides
- CJC-1295 (DAC)
- GHRH analogue with extended half-life
- 3–5 weeks
- 10–14 weeks
- DAC modification extends duration but delays peak response
- Sermorelin sits in the middle of the response spectrum. It's slower than GHRP-2 or MK-677 because it works exclusively through pituitary GHRH receptors, without the dual hypothalamic + pituitary action that ghrelin mimetics provide. It's faster than CJC-1295 DAC because its short half-life allows more frequent dosing aligned with natural GH pulses, rather than relying on sustained baseline elevation. For research protocols measuring morphometric or metabolic endpoints, sermorelin's 8–12 week peak response window requires study durations of at least 16 weeks to capture post-peak stabilisation. Shorter observation windows will miss the compound's true effect magnitude.